Integra LifeSciences (NASDAQ:IART) PT Lowered to $26.00

Integra LifeSciences (NASDAQ:IART) had its price target decreased by Bank of America from $42.00 to $26.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “underperform” rating on the life sciences company’s stock. Bank of America‘s price objective indicates a potential upside of 4.38% from the stock’s previous close.

Several other equities analysts have also recently commented on IART. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research note on Wednesday, April 3rd. Wells Fargo & Company lowered shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $45.00 to $25.00 in a research report on Tuesday. Truist Financial decreased their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. Oppenheimer downgraded Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Finally, StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $36.80.

Integra LifeSciences Stock Performance

Shares of IART opened at $24.91 on Tuesday. The company has a market capitalization of $1.96 billion, a PE ratio of 30.01, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. Integra LifeSciences has a one year low of $22.36 and a one year high of $50.78. The company’s fifty day moving average price is $32.67 and its 200 day moving average price is $38.15.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The business had revenue of $368.90 million during the quarter, compared to analysts’ expectations of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.74 EPS. As a group, analysts expect that Integra LifeSciences will post 3.19 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after buying an additional 72,294 shares in the last quarter. Capital Research Global Investors increased its holdings in Integra LifeSciences by 40.1% during the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after purchasing an additional 1,228,996 shares in the last quarter. Cooke & Bieler LP raised its position in Integra LifeSciences by 4.4% in the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after purchasing an additional 120,410 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Integra LifeSciences by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock valued at $70,340,000 after purchasing an additional 63,323 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Integra LifeSciences by 19.5% during the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after purchasing an additional 238,816 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.